Summary

Plasma Fractionation Market Growth & Trends

The global plasma fractionation market size is estimated to reach USD 58.24 billion by 2030, registering to grow at a CAGR of 8.5% from 2025 to 2030 according to a new report by Grand View Research, Inc. The major factors driving the market growth are the rising prevalence of respiratory illnesses globally, blood-related diseases, and an aging population that is prone to a variety of rare disorders. These are the main drivers of market expansion. In addition, the rise in the prevalence of rare disorders that call for plasma therapy or derivatives also supplemented the market growth.

The global market is also expanding due to the increased use of immunoglobulins as well as alpha-1-antitrypsin in various areas of research around the world. Another important factor for the expansion of the market is the rise in blood collection facilities globally. For instance, as per the WHO, as of May 2022, over 118 million blood donations were collected across the globe, thus increasing the plasma supply gradually. Additionally, supportive government initiatives to raise public awareness about the usage of plasma-derived products also serve as a major driver of the global market's expansion.

Blood plasma transfusions are one of the cutting-edge treatments for COVID-19 infection. For instance, in August 2020, the US Food and Drug Administration (USFDA) granted the convalescent plasma treatment of COVID-19 an emergency use authorization (EUA). Additionally, in February 2021, it published an amended directive for the plasma EUA for COVID-19. As a result, the usage of plasma fractionation technologies is projected to increase during the COVID-19 pandemic.

The growing demand for personalized medications has increased R&D spending, and technological advancements in plasma components such as immune serum globulin, which have advantages such as higher yield, lower cost, and faster throughput, are driving market growth. On the other hand, immunoglobulins generated from plasma are being employed more frequently for a variety of clinical conditions, including autoimmune and inflammatory illnesses. Therapies including Ceruloplasmin, IgA, and Plasmin have received significant funding from the plasma fractionation sector. Additionally, the industry will receive a boost from booming investments in innovation and technology developments that result in efficient and affordable methods for fractionating proteins. thus, propelling the market's growth.

For companies operating market-related businesses, the market offers a lot of opportunities. In addition, the global and regional market participants are actively implementing organic and inorganic development strategies as a result of the market's favorable expansion. As a result, it is anticipated that the market will draw more notable investments during the forecast period. For instance, in January 2022, the eighth plasma collection facility in the Czech Republic was opened by Biotest AG. The national public health authority, SUKL, granted the company an operating license for these centers.

Plasma Fractionation Market Report Highlights

• The immunoglobulins segment dominated the market in terms of revenue share of 63.2% in 2024 and is anticipated to grow at the fastest CAGR of 9.1%. fueled by its widespread use in treating immune deficiencies, autoimmune diseases, and neurological disorders.

• The chromatography segment dominated the market and accounted for a 33.7% share in 2024. The utilization of industrial-scale chromatographic fractionation as well as purification techniques for plasma fractionation has increased recently.

• The neurology segment held the largest revenue share of 30.0% in 2024, driven by the increasing recognition of plasma-derived therapies for neurological disorders. Conditions such as multiple sclerosis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy are increasingly being treated with therapies like intravenous immunoglobulin (IVIg) and plasmapheresis.

• The hospitals and clinics dominated the market with the largest revenue share of 53.4% in 2024 and are expected to grow at the fastest CAGR of 9.0% over the forecast period. This is driven by the increasing demand for plasma-derived therapies in various medical applications.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Method Segment
1.2.3. Application Segment
1.2.4. End use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Plasma Fractionation Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growing Demand For Advanced Treatment Options To Boost Market Growth
3.2.1.2. Growing Use Of Immunoglobulins In Various Therapeutic Areas
3.2.2. Market restraint analysis
3.2.2.1. Stringent Regulatory Policies
3.3. Plasma Fractionation Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Plasma Fractionation Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Plasma Fractionation Market Product Movement Analysis
4.3. Global Plasma Fractionation Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Billion)
4.4. Albumin
4.4.1. Albumin market estimates and forecasts 2018 to 2030 (USD Billion)
4.5. Immunoglobulins
4.5.1. Immunoglobulins market estimates and forecasts 2018 to 2030 (USD Billion)
4.5.2. Intravenous immunoglobulins
4.5.2.1. Intravenous immunoglobulins market estimates and forecasts 2018 to 2030 (USD Billion)
4.5.3. Subcutaneous immunoglobulins
4.5.3.1. Subcutaneous immunoglobulins market estimates and forecasts 2018 to 2030 (USD Billion)
4.5.4. Other immunoglobulins
4.5.4.1. Other immunoglobulins market estimates and forecasts 2018 to 2030 (USD Billion)
4.6. Coagulation Factors
4.6.1. Coagulation factors market estimates and forecasts 2018 to 2030 (USD Billion)
4.6.2. Factor VIII
4.6.2.1. Factor VIII market estimates and forecasts 2018 to 2030 (USD Billion)
4.6.3. Factor IX
4.6.3.1. Factor IX market estimates and forecasts 2018 to 2030 (USD Billion)
4.6.4. VON WILLEBRAND factor
4.6.4.1. VON WILLEBRAND factor market estimates and forecasts 2018 to 2030 (USD Billion)
4.6.5. Prothrombin complex concentrates
4.6.5.1. Prothrombin complex concentrates market estimates and forecasts 2018 to 2030 (USD Billion)
4.6.6. Fibrinogen concentrates
4.6.6.1. Fibrinogen concentrates market estimates and forecasts 2018 to 2030 (USD Billion)
4.6.7. Others
4.6.7.1. Others factor market estimates and forecasts 2018 to 2030 (USD Billion)
4.7. Protease inhibitors
4.7.1. Protease inhibitors market estimates and forecasts 2018 to 2030 (USD Billion)
4.8. Others
4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 5. Plasma Fractionation Market: Method Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Plasma Fractionation Market Method Movement Analysis
5.3. Global Plasma Fractionation Market Size & Trend Analysis, by Method, 2018 to 2030 (USD Billion)
5.4. Centrifugation
5.4.1. Centrifugation market estimates and forecasts 2018 to 2030 (USD Billion)
5.5. Depth Filtration
5.5.1. Depth filtration market estimates and forecasts 2018 to 2030 (USD Billion)
5.6. Chromatography
5.6.1. Chromatography market estimates and forecasts 2018 to 2030 (USD Billion)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 6. Plasma Fractionation Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Plasma Fractionation Market Application Movement Analysis
6.3. Global Plasma Fractionation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Billion)
6.4. Neurology
6.4.1. Neurology market estimates and forecasts 2018 to 2030 (USD Billion)
6.5. Hematology
6.5.1. Hematology market estimates and forecasts 2018 to 2030 (USD Billion)
6.6. Oncology
6.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Billion)
6.7. Immunology
6.7.1. Immunology market estimates and forecasts 2018 to 2030 (USD Billion)
6.8. Pulmonology
6.8.1. Pulmonology market estimates and forecasts 2018 to 2030 (USD Billion)
6.9. Others
6.9.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 7. Plasma Fractionation Market: End-use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Plasma Fractionation Market End-use Movement Analysis
7.3. Global Plasma Fractionation Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Billion)
7.4. Hospitals & Clinics
7.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Billion)
7.5. Clinical Research
7.5.1. Clinical research market estimates and forecasts 2018 to 2030 (USD Billion)
7.6. Others
7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 8. Plasma Fractionation Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. U.S.
8.4.1.1. Key country dynamics
8.4.1.2. Competitive scenario
8.4.1.3. Regulatory framework
8.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
8.4.2. Canada
8.4.2.1. Key country dynamics
8.4.2.2. Competitive scenario
8.4.2.3. Regulatory framework
8.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
8.4.3. Mexico
8.4.3.1. Key country dynamics
8.4.3.2. Competitive scenario
8.4.3.3. Regulatory framework
8.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
8.5. Europe
8.5.1. UK
8.5.1.1. Key country dynamics
8.5.1.2. Competitive scenario
8.5.1.3. Regulatory framework
8.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.2. Germany
8.5.2.1. Key country dynamics
8.5.2.2. Competitive scenario
8.5.2.3. Regulatory framework
8.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.3. France
8.5.3.1. Key country dynamics
8.5.3.2. Competitive scenario
8.5.3.3. Regulatory framework
8.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.4. Italy
8.5.4.1. Key country dynamics
8.5.4.2. Competitive scenario
8.5.4.3. Regulatory framework
8.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.5. Spain
8.5.5.1. Key country dynamics
8.5.5.2. Competitive scenario
8.5.5.3. Regulatory framework
8.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.6. Denmark
8.5.6.1. Key country dynamics
8.5.6.2. Competitive scenario
8.5.6.3. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.7. Sweden
8.5.7.1. Key country dynamics
8.5.7.2. Competitive scenario
8.5.7.3. Regulatory framework
8.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
8.5.8. Norway
8.5.8.1. Key country dynamics
8.5.8.2. Competitive scenario
8.5.8.3. Regulatory framework
8.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
8.6. Asia Pacific
8.6.1. Japan
8.6.1.1. Key country dynamics
8.6.1.2. Competitive scenario
8.6.1.3. Regulatory framework
8.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.2. China
8.6.2.1. Key country dynamics
8.6.2.2. Competitive scenario
8.6.2.3. Regulatory framework
8.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.3. India
8.6.3.1. Key country dynamics
8.6.3.2. Competitive scenario
8.6.3.3. Regulatory framework
8.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.4. Australia
8.6.4.1. Key country dynamics
8.6.4.2. Competitive scenario
8.6.4.3. Regulatory framework
8.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.5. South Korea
8.6.5.1. Key country dynamics
8.6.5.2. Competitive scenario
8.6.5.3. Regulatory framework
8.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
8.6.6. Thailand
8.6.6.1. Key country dynamics
8.6.6.2. Competitive scenario
8.6.6.3. Regulatory framework
8.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
8.7. Latin America
8.7.1. Brazil
8.7.1.1. Key country dynamics
8.7.1.2. Competitive scenario
8.7.1.3. Regulatory framework
8.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
8.7.2. Argentina
8.7.2.1. Key country dynamics
8.7.2.2. Competitive scenario
8.7.2.3. Regulatory framework
8.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
8.8. MEA
8.8.1. South Africa
8.8.1.1. Key country dynamics
8.8.1.2. Competitive scenario
8.8.1.3. Regulatory framework
8.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
8.8.2. Saudi Arabia
8.8.2.1. Key country dynamics
8.8.2.2. Competitive scenario
8.8.2.3. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
8.8.3. UAE
8.8.3.1. Key country dynamics
8.8.3.2. Competitive scenario
8.8.3.3. Regulatory framework
8.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
8.8.4. Kuwait
8.8.4.1. Key country dynamics
8.8.4.2. Competitive scenario
8.8.4.3. Regulatory framework
8.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Grifols S.A.
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. CSL Limited
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Takeda Pharmaceutical Company Limited
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Octapharma AG
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Kedrion S.p.A
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. LFB S.A.
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Biotest AG
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Sanquin
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Bio Products Laboratory Ltd.
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Intas Pharmaceuticals Ltd
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives